GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

NCT00252876 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2000

Enrollment

INDUSTRY

Sponsor class

Stopped The development program has been terminated

Conditions

Type 2 Diabetes

Interventions

DRUG: tesaglitazar

Sponsor

AstraZeneca